1. Home
  2. TEL vs ARGX Comparison

TEL vs ARGX Comparison

Compare TEL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TE Connectivity Ltd. New Switzerland Registered Shares

TEL

TE Connectivity Ltd. New Switzerland Registered Shares

N/A

Current Price

$213.72

Market Cap

62.6B

Sector

Technology

ML Signal

N/A

Logo argenx SE

ARGX

argenx SE

N/A

Current Price

$895.47

Market Cap

55.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TEL
ARGX
Founded
1941
2008
Country
Ireland
Netherlands
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
62.6B
55.1B
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
TEL
ARGX
Price
$213.72
$895.47
Analyst Decision
Buy
Buy
Analyst Count
19
23
Target Price
$257.53
★ $1,147.35
AVG Volume (30 Days)
★ 1.5M
458.2K
Earning Date
10-28-2026
10-22-2026
Dividend Yield
★ 1.40%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 7.98
N/A
Revenue
★ $17,262,000,000.00
N/A
Revenue This Year
$12.55
$50.41
Revenue Next Year
$6.98
$22.01
P/E Ratio
★ $28.03
$33.69
Revenue Growth
★ 8.94
N/A
52 Week Low
$190.27
$661.85
52 Week High
$252.56
$1,072.75

Technical Indicators

Market Signals
Indicator
TEL
ARGX
Relative Strength Index (RSI) 48.85 50.46
Support Level $196.68 $831.19
Resistance Level $222.46 $941.15
Average True Range (ATR) 7.07 24.96
MACD 0.31 9.56
Stochastic Oscillator 34.98 80.46

Price Performance

Historical Comparison
TEL
ARGX

About TEL TE Connectivity Ltd. New Switzerland Registered Shares

TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: